Policy & Regulation
Insurance Denied Your GLP-1—What Can You Actually Do Next?
How U.S. GLP-1 prices and insurance denials drive patients toward cash pay, compounding and the grey market—and what each pathway proves.
Department
Policy & Regulation
Reporting and analysis from the Research Pep News inaugural archive.
Policy & Regulation
Retatrutide — Will It Cost $1,500 per Month?
Lilly’s biologics strategy could keep retatrutide free from biosimilar competition for 12 years as forecasts place its launch price as high as $1,500 a month.
Policy & Regulation
Novo Nordisk Sued Hims & Hers Over a $49 ‘Wegovy Copy’—Then They Made a Deal
Hims launched a $49 compounded semaglutide pill, withdrew it after FDA pressure and a Novo Nordisk legal threat, then became Novo’s partner.
Policy & Regulation
FDA Panel Backs Six Peptides. Here’s What the Vote Actually Changes.
FDA advisers backed BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon for the 503A Bulks List. Here’s what the vote means.
Policy & Regulation
Update: Peptide Legislation, FDA Regulation, and RFK Jr.’s Role in the 2026 Peptide Debate
A research-focused update on federal policy, compounding reviews, access arguments, and the political figures shaping the debate.